CuraSen Therapeutics Revenue
Biotechnology Research • 
San Carlos, California, United States • 11-20 Employees
CuraSen Therapeutics revenue & valuation
| Annual revenue | $6,500,000 |
| Revenue per employee | $325,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $20,800,000 |
| Total funding | $11,600,000 |
Key Contacts at CuraSen Therapeutics
Michael Dillon
Chief Technology Officer
David Carter
Senior Director Of Chemistry
Joel Gever
Senior Director Of Pharmacology
Judy Reynolds
Senior Director Clinical Operations
Anthony Ford
Ceo
Company overview
| Headquarters | 930 Brittan Ave, #306, San Carlos, California 94070, US |
| Phone number | +16504752842 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Neurodegeneration, Parkinson’S Disease, Neuroinflammation, Alzheimer’S Disease, Locus Coeruleus, Neurometabolism, Cerebral Blood Flow |
| Founded | 2017 |
| Employees | 11-20 |
| Socials |
CuraSen Therapeutics Email Formats
CuraSen Therapeutics uses 1 email format. The most common is {last name} (e.g., doe@curasen.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{last name} | doe@curasen.com | 100% |
About CuraSen Therapeutics
It’s time to think again about therapies for neurodegenerative disease. At CuraSen, we are targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN. CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease, as well as several orphan indications. Millions of patients and their families are burdened by these diseases, and the numbers continue to grow annually with the aging population. At CuraSen, we are rethinking the therapeutic approach to treatment of neurodegenerative diseases—and advancing a concept based on restoring a key functionality to a pathway lost early in the degenerating brain. This pathway emanates from the locus coeruleus (LC), site of the earliest pathology seen in these diseases – perhaps the ‘hypocenter’ of neurodegeneration. We began clinical testing of our hypothesis in 2019 using established drugs from other therapeutic areas, which has informed our development program and helped advance our first new chemical entity, CST-2032, to the clinic in September 2020. CuraSen has assembled an impressive team, deeply experienced in the neuroscience, pharmacology and clinical development core to its approach, as well as top tier investor backing, including New Leaf Venture Partners, Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and Pappas Capital.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
CuraSen Therapeutics has 9 employees across 5 departments.
Departments
Number of employees
Funding Data
Explore CuraSen Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
CuraSen Therapeutics Tech Stack
Discover the technologies and tools that power CuraSen Therapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Font scripts
JavaScript libraries
Tag managers
Reverse proxies
Programming languages
Miscellaneous
Blogs
Miscellaneous
JavaScript libraries
Analytics
Databases
Australia
United Kingdom
Canada
Frequently asked questions
4.8
40,000 users
